American Association for Cancer Research
00085472can140389-sup-126795_1_supp_2519837_n79bjj.png (195.04 kB)

Supplemental Figure S1 from Metastatic Heterogeneity of Breast Cancer Cells Is Associated with Expression of a Heterogeneous TGFβ-Activating miR424–503 Gene Cluster

Download (195.04 kB)
posted on 2023-03-30, 23:09 authored by Yun Li, Wei Li, Zhe Ying, Han Tian, Xun Zhu, Jun Li, Mengfeng Li

Supplemental Figure S1. Relative expression of miR-424 was plotted against expression of miR-503 in breast cancer cell lines and breast cancer tissues.



TGFβ signaling is known to drive metastasis in human cancer. Under physiologic conditions, the level of TGFβ activity is tightly controlled by a regulatory network involving multiple negative regulators. At metastasis, however, these inhibitory mechanisms are usually overridden so that oncogenic TGFβ signaling can be overactivated and sustained. To better understand how the TGFβ inhibitors are suppressed in metastatic breast cancer cells, we compared miRNA expression profiles between breast cancers with or without metastasis and found that the miR424–503 cluster was markedly overexpressed in metastatic breast cancer. Mechanistic studies revealed that miR424 and miR503 simultaneously suppressed Smad7 and Smurf2, two key inhibitory factors of TGFβ signaling, leading to enhanced TGFβ signaling and metastatic capability of breast cancer cells. Moreover, antagonizing miR424–503 in breast cancer cells suppressed metastasis in vivo and increased overall host survival. Interestingly, our study also found that heterogeneous expression of the miR424–503 cluster contributed to the heterogeneity of TGFβ activity levels in, and metastatic potential of, breast cancer cell subsets. Overall, our findings demonstrate a novel mechanism, mediated by elevated expression of the miR424–503 cluster, underlying TGFβ activation and metastasis of human breast cancer. Cancer Res; 74(21); 6107–18. ©2014 AACR.

Usage metrics

    Cancer Research



    Ref. manager